Blog

Combined inhibition of IL1 IL33 and IL36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis – The BMJ



Published on: 2024-08-27

Combined inhibition of IL1 IL33 and IL36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis - The BMJ - Image 1

Combined inhibition of IL1 IL33 and IL36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis - The BMJ - Image 2

Combined inhibition of IL1 IL33 and IL36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis - The BMJ - Image 3

Combined inhibition of IL1 IL33 and IL36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis - The BMJ - Image 4